Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.34 |
| ▸ | TNF | P01375 | 2/20 | 0.33 |
| ▸ | ADRB3 | P13945 | 8/20 | 0.33 |
| ▸ | MPO | P05164 | 3/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.32 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.31 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21600577 | 0.80 | HTR1A (0.43) | HTR1AGPR84TNFMPOSLC6A4 | |
| SCHEMBL5387311 | 0.77 | HTR1A (0.48) | HTR1AGPR84MPOSLC6A4HTR2A | |
| SCHEMBL5392766 | 0.73 | HTR1A (0.38) | HTR1AGPR84TNFMPOSLC6A4 | |
| SCHEMBL19216724 | 0.71 | HTR1A (0.36) | HTR1AGPR84 | |
| SCHEMBL30457622 | 0.67 | HTR1A (0.33) | HTR1AGPR84 | |
| SCHEMBL20576934 | 0.67 | ALDH1A1 (0.35) | HTR1AGPR84TNF | |
| SCHEMBL16986776 | 0.66 | ALOX15 (0.39) | HTR2AHTR2C | |
| SCHEMBL28477011 | 0.66 | NOS3 (0.40) | HTR2A | |
| SCHEMBL3459241 | 0.66 | ALOX15 (0.39) | HTR2AHTR2C | |
| SCHEMBL31730632 | 0.65 | TNF (0.64) | HTR1ATNFMPOSLC6A4HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7217730-B2 | Method for the use of pyranoindole derivatives to treat infection with Hepatitis C virus | WYETH (US) | 2007-05-15 | — | — | US | disclosed |
| CN-1655778-A | Methods of treating hepatitis C virus infection using pyranoindole derivatives | WYETH CORP (US) | 2005-08-17 | — | — | CN | disclosed |
| EP-1509225-A1 | METHOD FOR THE USE OF PYRANOINDOLE DERIVATIVES TO TREAT INFECTION WITH HEPATITIS C VIRUS | Wyeth (US) | 2005-03-02 | — | — | EP | disclosed |
| US-20040082643-A1 | Method for the use of pyranoindole derivatives to treat infection with Hepatitis C virus | WYETH (US) | 2004-04-29 | — | — | US | disclosed |
| WO-2003099275-A1 | METHOD FOR THE USE OF PYRANOINDOLE DERIVATIVES TO TREAT INFECTION WITH HEPATITIS C VIRUS | WYETH (US) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082643-A1 | Method for the use of pyranoindole derivatives to treat infection with Hepatitis C virus | HAVCR2, HCCS, ZC3HAV1 | HTR1A 347/4885GPR84 2156/4885TNF 2317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.